30 episodes

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Rheumatology, Immunology, and Infectious Diseases by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions from rheumatology, immunology, and infectious diseases. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases Answers In CME

    • Science
    • 5.0 • 4 Ratings

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Rheumatology, Immunology, and Infectious Diseases by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions from rheumatology, immunology, and infectious diseases. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

    Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

    Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

    Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

    • 12 min
    Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

    Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

    Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.

    • 15 min
    Juliana M. Kling, MD, MPH - Improving Inclusive Care: Enhancing HPV Vaccine Uptake Among LGBTQ+ Individuals

    Juliana M. Kling, MD, MPH - Improving Inclusive Care: Enhancing HPV Vaccine Uptake Among LGBTQ+ Individuals

    Please visit answersincme.com/GHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses improving human papillomavirus (HPV) vaccination uptake among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals. Upon completion of this activity, participants should be better able to: Identify the clinical impact of low uptake of HPV vaccination among LGBTQ+ individuals; Review the clinical profiles and suggested administration of guideline-recommended HPV vaccines; and Outline patient-centered strategies to enhance acceptance of HPV vaccination among LGBTQ+ individuals.

    • 15 min
    John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

    John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

    Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.

    • 14 min
    Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

    Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

    Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.

    • 14 min
    Nicola A. Hanania, MD, MS - Enough: Targeting Eosinophilic Pathways With Biologics in Chronic Obstructive Pulmonary Disease

    Nicola A. Hanania, MD, MS - Enough: Targeting Eosinophilic Pathways With Biologics in Chronic Obstructive Pulmonary Disease

    Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

    • 15 min

Customer Reviews

5.0 out of 5
4 Ratings

4 Ratings

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Sean Carroll's Mindscape: Science, Society, Philosophy, Culture, Arts, and Ideas
Sean Carroll | Wondery
Radiolab
WNYC Studios
Crash Course Pods: The Universe
Crash Course Pods, Complexly
Ologies with Alie Ward
Alie Ward

You Might Also Like

The Immunology Podcast
The Immunology Podcast
This Week in Parasitism
Vincent Racaniello
This Week in Virology
Vincent Racaniello
Infectious Disease Puscast
Vincent Racaniello